Intermediate-risk neuroblastoma: lines of therapy
4 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Other settings | 4 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Chemotherapy | Two to eight cycles of carboplatin, etoposide, cyclophosphamide and doxorubicin by biology and response (A3961, ANBL0531), then surgery when resectable. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 94 | |
| All comers | Response assessment and surgery | MRI or CT and MIBG scan after chemotherapy; resection of the residual primary where safe, otherwise observation of the residual mass. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 58 | |
| All comers | Non-responding or life-threatening disease | Radiotherapy to the primary or to a compressing lesion; escalation to high-risk therapy if biology proves unfavourable. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 93 | |
| All comers | Follow-up | Hearing, kidney, cardiac and fertility follow-up for the chemotherapy given. | NCI PDQ: Neuroblastoma Treatment (health professional version) | 79 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.